Bei Dai

Ms. Bei Dai

department of pathology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Bei DaiBei Dai
Bei Dai
Amanda M ClarkAmanda M Clark
Amanda M Clark
Alan WellsAlan Wells
Alan Wells
Breast cancer is most common in women, and in most cases there is no evidence of spread and the primary tumor is removed, resulting in a ‘cure’. However, in 10% to 30% of these women, distant metastases recur after years to decades. This is due to breast cancer cells disseminating to distant organs and lying quiescent. This is called metastatic dormancy. Dormant cells are generally resistant to chemotherapy, hormone therapy and immunotherapy as they are non-cycling and receive survival signals from their microenvironment. In this state, they are clinically irrelevant. However, risk factors, including aging and inflammation can awaken dormant cells and cause breast cancer recurrences, which may happen even more than ten years after the primary tumor removal. How these breast cancer cells remain in dormancy is being unraveled. A key element appears to be the mesenchymal stem cells in the bone marrow that have been shown to promote breast cancer metastatic dormancy in recent studies. Indirect co-culture, direct co-culture and exosome extraction were conducted to investigate the modes of signal operation. Multiple signaling molecules act in this process including both protein factors and microRNAs. We integrate these studies to summarize current findings and gaps in the field and suggest future research directions for this field.

26 August 2025 in Cells
Verified
Journal Article
Open access
PDF file
Bei DaiBei Dai
Bei Dai
NANeha Atale
Neha Atale
Amanda M ClarkAmanda M Clark
Amanda M Clark
Alan WellsAlan Wells
Alan Wells
The major event that leads to death from breast cancer (BrCa) is the emergence of micrometastases into lethal growing metastases. While it is still uncertain what regulates the cell fate decision between remaining in dormancy and aggressive proliferative progression, accumulating evidence demonstrates a major role for the metastatic microenvironment. One area of interest is that of tissue and circulating mesenchymal stem cells (MSCs), which have been shown to alter the proliferative and metastatic potential of BrCa. Herein, we investigate how these cells impact the phenotype of metastatic BrCa. As the disseminated BrCa cells initially adopt an epithelial phenotype in ectopic organs, one that is dormant in having limited proliferation and being immune-silent, interactions that revert the disseminated metastatic BrCa to aggressive mesenchymal phenotypes, would be a driver of metastatic progression. BrCa cells exhibited phenotypic changes including increased E-cadherin expression, altered proliferation, and differential sensitivity to TRAIL-induced apoptosis when directly co-cultured with immortalized human MSCs, compared to the BrCa cells not co-cultured. These regulatory effects were dependent upon the BrCa cell’s epithelial–mesenchymal status and involved distinct juxtacrine and paracrine signaling mechanisms, as evidenced by differing responses in direct co-culture, conditioned medium, and Transwell systems. Our findings highlight the complex and context-dependent roles of MSCs in BrCa progression, improving our understanding of tumor-stroma interactions and laying groundwork for future therapeutic exploration.

13 June 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
Bei DaiBei Dai
Bei Dai
Breast cancer is the most common cancer in women worldwide. Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, while estrogen receptor-positive breast cancer (ER+BC) exhibits the longest dormancy phenomenon, wherein breast cancers recur as distant metastases even decades after removal of the primary tumor. Therefore, this study will focus on both TNBC and ER+BC. The majority of breast cancer-related deaths are attributed to breast cancer metastasis, while E-cadherin is integral in the metastasis process with its downregulation enabling escape from the primary tumor site, and its re-expression enabling the survival of disseminated tumor cells (DTCs) when they seed the metastatic site. Mesenchymal stem cells (MSCs) were previously shown to be recruited to the primary breast cancer site and also to be present in the breast cancer metastasis. Their wide distribution allows them to act on both primary and metastatic tumor cells. We are expanding this research area to determine how MSCs regulate the more epithelial-mesenchymal phenotypes including immuno-resistance, proliferation, and E-cadherin-mediated interactions with parenchymal cells. Our preliminary results demonstrate that MSCs inhibit the E-cadherin level of specific TNBC cell lines and enhance the proliferation of TNBC cells and ER+BC cells; thus driving a more progressive phenotype. Fas ligand (FasL)-induced apoptosis will be measured to represent the non-specific immune responses. After that, whether this signal is paracrine or juxtacrine will be determined by the results of direct co-culture and indirect co-culture experiments including Transwell co-culture and conditioned media (CM) experiments. Signaling molecule screening will be performed by siRNA library screening, multiplex immunoassay, or small RNA sequencing to look for possible therapeutic targets, with the specific screening method is dependent on the co-culture results. Finally, we will confirm our conclusions including the effect on epithelial-mesenchymal phenotypes of BCCs and screened signal molecules in animal models and ex vivo MPS models which mimic human liver microenvironments. By studying the mechanism behind this regulation, we hope to define a new therapeutic approach to suppress the metastatic outgrowth of dormant breast cancer. Citation Format: Bei Dai. Mesenchymal Stem Cells Regulate E-cadherin Level, Proliferation, and Immuno-Resistance on Breast Cancer Cells [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2024; 2024 Dec 10-13; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2025;31(12 Suppl):Abstract nr P3-07-30.